Abiopharma

🔍 Yarema Kristin (Executive)

Company: ImageneBio, Inc. (IMA)

Report Date: 2026-07-25

Detailed Transactions and Holdings:

• Acquired 38,376 shares of Common Stock (Direct)
  Date: 2026-07-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 123,776.00 | transaction_form_type: 4
• Acquired 115,129 shares of Common Stock (Direct)
  Date: 2026-07-25 | Code: J | equity_swap_involved: 0 | shares_owned_after: 238,905.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1
• Sold 38,376 shares of Restricted Stock Units (Derivative)
  Date: 2026-07-25 | Code: M | equity_swap_involved: 0 | shares_owned_after: 115,129.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3
• Sold 115,129 shares of Restricted Stock Units (Derivative)
  Date: 2026-07-25 | Code: J | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F3, F3

Footnotes:

• F1: On July 28, 2025, the Reporting Person was granted restricted stock units ("RSUs"), which RSUs were previously reported in Table II. Effective with this filing, the Reporting Person has elected to report grants of RSUs that are settleable solely in shares of the Issuer's common stock in Table I as acquisitions of common stock, rather than in Table II as derivative securities. Previously reported unvested RSUs that had been reported in Table II are included in the amount of securities beneficially owned shown in Column 5 of Table I. The 115,129 unvested RSUs carried over from prior Table II reporting represent grant awarded on July 28, 2025 that vests on the schedule described in footnote 3. As reported in Column 9 of Table II, there are no remaining RSUs that settle in common stock.
• F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• F3: The RSUs vest over four years, with 25% of the shares subject to RSUs vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal quarterly installments over the following 12 quarterly dates.